[LXRX] Lexicon Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.18 Change: 0.94 (6.6%)
Ext. hours: Change: 0 (0%)

chart LXRX

Refresh chart

Strongest Trends Summary For LXRX

LXRX is in the medium-term down -60% in 1 year. In the long-term down -78% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinic

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 165.09% Sales Growth - Q/Q-91.66% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.93% ROE-37.86% ROI
Current Ratio7.45 Quick Ratio Long Term Debt/Equity Debt Ratio0.18
Gross Margin Operating Margin-395.67% Net Profit Margin-400.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-830 K Cash From Investing Activities-70.99 M Cash From Operating Activities-23.48 M Gross Profit
Net Profit-28.08 M Operating Profit-26.53 M Total Assets444.68 M Total Current Assets342.31 M
Total Current Liabilities45.93 M Total Debt107.21 M Total Liabilities187.07 M Total Revenue1.79 M
Technical Data
High 52 week13.69 Low 52 week4.36 Last close5.19 Last change2.77%
RSI21.91 Average true range0.5 Beta1.6 Volume987.44 K
Simple moving average 20 days-12.67% Simple moving average 50 days-22.44% Simple moving average 200 days-45.82%
Performance Data
Performance Week19.04% Performance Month-28.12% Performance Quart-37.62% Performance Half-52.34%
Performance Year-46.85% Performance Year-to-date-21.84% Volatility daily6.95% Volatility weekly15.55%
Volatility monthly31.86% Volatility yearly110.36% Relative Volume448.21% Average Volume645.07 K
New High New Low

News

2019-03-19 19:05:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-19 16:25:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm

2019-03-18 10:36:00 | GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action

2019-03-18 07:25:11 | Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

2019-03-15 15:00:00 | LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019

2019-03-15 10:39:24 | Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

2019-03-15 07:48:10 | Lexicon Pharmaceuticals Inc LXRX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-14 20:57:13 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-13 13:49:55 | Lexicon Pharmaceuticals, Inc. LXRX Q4 2018 Earnings Conference Call Transcript

2019-03-13 13:32:18 | Edited Transcript of LXRX earnings conference call or presentation 13-Mar-19 12:00pm GMT

2019-03-13 08:15:12 | Lexicon Pharmaceuticals LXRX Reports Q4 Loss, Tops Revenue Estimates

2019-03-13 07:22:11 | Lexicon: 4Q Earnings Snapshot

2019-03-13 07:00:00 | Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update

2019-03-13 06:00:00 | Lexicon Pharmaceuticals, Inc. to Host Earnings Call

2019-03-12 20:00:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-12 10:32:00 | LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action & Deadline: April 1, 2019

2019-03-12 10:27:49 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-03-12 08:52:12 | Do Options Traders Know Something About Lexicon Pharmaceuticals LXRX Stock We Don't?

2019-03-11 16:00:00 | Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019

2019-03-11 10:31:00 | LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Deadline: April 1, 2019

2019-03-11 07:00:00 | Lexicon Pharmaceuticals to Present at Upcoming Investor Conference 

2019-03-08 10:15:03 | Zacks.com featured highlights include: Lexicon, Medtronic and NetApp

2019-03-07 19:24:56 | SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-07 18:20:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

2019-03-07 14:09:46 | LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019

2019-03-07 07:52:12 | 3 Stocks That Flaunt Solid Earnings Acceleration

2019-03-05 22:50:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-05 10:25:00 | STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. LXRX, ProShares Short VIX Short-Term Futures ETF SVXY & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II AMR

2019-03-05 09:00:00 | Deadline in Lawsuit for Investors in shares of Lexicon Pharmaceuticals, Inc. NASDAQ: LXRX announced by Shareholders Foundation

2019-03-05 08:07:48 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-03-04 12:04:00 | LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019

2019-03-04 10:25:00 | INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. LXRX, ProShares Short VIX Short-Term Futures ETF SVXY & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II AMR

2019-03-03 18:04:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019

2019-03-03 10:24:00 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. LXRX, ProShares Short VIX Short-Term Futures ETF SVXY & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II AMR

2019-03-01 12:16:00 | Here's Why Lexicon Pharmaceuticals Jumped as Much as 26.9% Today

2019-03-01 08:02:02 | Sanofi : CHMP recommends ZynquistaTM sotagliflozin for the treatment of adults with type 1 diabetes

2019-03-01 08:00:00 | CHMP Recommends Zynquista™ Sotagliflozin for the Treatment of Adults With Type 1 Diabetes

2019-02-28 17:26:10 | Lexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference

2019-02-28 15:18:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Deadline: April 1, 2019

2019-02-28 14:39:19 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-02-28 12:18:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Deadline: April 1, 2019

2019-02-28 10:29:00 | VALE, LXRX & SVXY: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action

2019-02-27 15:17:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019

2019-02-27 12:17:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action & Lead Plaintiff Deadline: April 1, 2019

2019-02-27 10:29:00 | VALE, LXRX & SVXY: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action

2019-02-26 19:44:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX

2019-02-26 15:20:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

2019-02-26 14:16:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action & Lead Plaintiff Deadline: April 1, 2019

2019-02-26 12:16:00 | Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Lead Plaintiff Deadline: April 1, 2019

2019-02-26 10:28:00 | VALE, LXRX & SVXY ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action